Akira Ono Selected Research

Akira Ono Research Topics

Disease

78	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2022 - 09/2008
53	Neoplasms (Cancer) 09/2022 - 03/2009
16	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 08/2007
12	Lung Neoplasms (Lung Cancer) 09/2022 - 09/2008
12	Neoplasm Metastasis (Metastasis) 12/2021 - 12/2011
10	Infections 12/2021 - 08/2004
8	Disease Progression 01/2020 - 12/2011
8	Adenocarcinoma of Lung 02/2018 - 05/2012
7	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2021 - 07/2011
6	Adenocarcinoma 01/2017 - 11/2008
5	Neutropenia 01/2020 - 03/2014
4	Pneumonia (Pneumonitis) 04/2022 - 10/2020
4	Cachexia 01/2022 - 11/2017
3	Thymoma (Thymic Carcinoma) 01/2014 - 02/2010
2	Inflammation (Inflammations) 01/2022 - 01/2019
2	Hemorrhage 01/2022 - 09/2013
2	Radiation Pneumonitis 03/2021 - 01/2020
2	Lead Poisoning (Poisoning, Lead) 01/2021 - 01/2021
2	Anorexia 01/2020 - 06/2015
2	Febrile Neutropenia 01/2020 - 06/2017
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2018 - 07/2013
2	Pleural Effusion (Pleural Effusions) 07/2014 - 05/2014
2	Dehydration (Water Stress) 04/2014 - 07/2013
1	Weight Loss (Weight Reduction) 02/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Sclerosing Cholangitis 04/2021
1	Cataract (Cataracts) 03/2021
1	Body Weight (Weight, Body) 06/2020
1	Human Influenza (Influenza) 01/2020
1	Diarrhea 01/2020
1	Melanoma (Melanoma, Malignant) 01/2020
1	Esophagitis 01/2020
1	Malnutrition (Nutritional Deficiencies) 01/2019
1	Brain Neoplasms (Brain Tumor) 01/2019

Drug/Important Bio-Agent (IBA)

23	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2008
19	Tyrosine Kinase InhibitorsIBA 12/2021 - 09/2008
16	PlatinumIBA 11/2019 - 08/2007
13	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 03/2009
9	Biomarkers (Surrogate Marker)IBA 04/2021 - 11/2011
7	Gefitinib (Iressa)FDA Link 01/2020 - 07/2009
6	Immune Checkpoint InhibitorsIBA 02/2022 - 01/2020
6	B7-H1 AntigenIBA 02/2022 - 12/2018
6	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2019
6	Docetaxel (Taxotere)FDA Link 10/2019 - 11/2008
5	durvalumabIBA 04/2022 - 10/2020
5	osimertinibIBA 11/2021 - 01/2020
5	amrubicinIBA 11/2019 - 08/2007
5	Vinorelbine (Navelbine)FDA LinkGeneric 09/2017 - 03/2009
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 04/2010
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 05/2009
4	pembrolizumabIBA 01/2022 - 05/2020
4	Etoposide (VP 16)FDA LinkGeneric 11/2019 - 02/2013
4	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 02/2010
3	antigen CYFRA21.1IBA 01/2020 - 07/2013
3	Pemetrexed (MTA)FDA Link 01/2020 - 03/2014
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 07/2009
3	NivolumabIBA 02/2018 - 01/2017
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 06/2013
2	Therapeutic UsesIBA 01/2022 - 11/2011
2	Angiogenesis InhibitorsIBA 01/2022 - 11/2021
2	ASP3026IBA 03/2021 - 01/2016
2	Anaplastic Lymphoma KinaseIBA 03/2021 - 01/2019
2	AcidsIBA 01/2021 - 11/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 04/2014
2	Bevacizumab (Avastin)FDA Link 11/2016 - 06/2013
2	pro-gastrin-releasing peptide (31-98)IBA 01/2015 - 06/2012
2	Formaldehyde (Formol)FDA Link 07/2014 - 05/2014
2	ParaffinIBA 07/2014 - 05/2014
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2014 - 05/2011
2	Thymidylate SynthaseIBA 01/2014 - 01/2014
2	Peptides (Polypeptides)IBA 06/2012 - 08/2004
1	Surface Antigens (Surface Antigen)IBA 09/2022
1	RamucirumabIBA 01/2022
1	LigandsIBA 04/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2021
1	Alanine Transaminase (SGPT)IBA 03/2021
1	Circulating Tumor DNAIBA 01/2021
1	Aminolevulinic Acid (Levulan)FDA Link 01/2021
1	Food Additives (Food Additive)IBA 06/2020
1	CadmiumIBA 06/2020
1	LectinsIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2019
1	alectinibIBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 11/2017
1	Blood Proteins (Serum Proteins)IBA 11/2017
1	AlbuminsIBA 11/2017
1	Dexamethasone (Maxidex)FDA LinkGeneric 09/2017
1	Aprepitant (Emend)FDA Link 09/2017

Therapy/Procedure

47	Drug Therapy (Chemotherapy) 02/2022 - 08/2007
30	Therapeutics 09/2022 - 09/2008
17	Chemoradiotherapy 01/2022 - 12/2009
16	Radiotherapy 07/2021 - 05/2011
6	Aftercare (After-Treatment) 11/2021 - 05/2011
5	Adjuvant Chemotherapy 09/2017 - 03/2009
3	Immunotherapy 01/2022 - 01/2021
2	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 01/2013
1	Cranial Irradiation 04/2018
1	Activities of Daily Living (ADL) 11/2017
1	Length of Stay 11/2017